-
Your voice counts! Tell the FDA you Support Action Against Indoor Tanning Devices. The Deadline to Comment is August 7, 2013
Calling all SDPA members! Recently the FDA issued a proposed order to reclassify sunlamps and indoor tanning beds from a Class I to Class II device. According to the AAD, indoor tanning devices are currently in Class I, the category for items that have minimal potential to cause harm to […]
July 26, 2013
-
LIVE BLOG: Sunscreen Controversies (and so-called Vitamin D Deficiency”) “
In this live blog from the SDPA Summer Conference in St. Louis, Dr. James Spencer educates us on the real truth behind “vitamin D deficiency,” and gives pearls of wisdom on sunscreen in the USA. In terms of vitamin D, keep in mind that the term “deficiency” used to […]
June 29, 2013
-
BREAKING NEWS: SDPA Helps Shift Controversial AMA Board Judgment on PAs in Surgery
Immediate SDPA past-president John Notabartolo sits down with Dermcast to talk about the recent AMA board decision victory for PAs. What’s the background of this issue? The AMA last year had looked at doing something that addressed policy concerning invasive procedures specific to pain management. This ended up […]
June 29, 2013
-
LIVE BLOG: New Approaches to the Lower Extremities & Venous Disease
In this live blog from the SDPA Summer Conference in St. Louis, Jeffery E. Petersen lectured on new approaches to treating skin diseases on the lower extremities. Venous Anatomy Deep venous system + Thigh Common femoral Femoral vein (superficial femoral) (deep vein) Profunda Popliteal + Calf Posterior tibial Anterior […]
June 29, 2013
-
LIVE BLOG: Treating Actinic Keratoses with Zyclara [Product Theater: Valeant]
In this interesting live blog from the SDPA Summer Conference, we address ZYCLARA Cream as a topical treatment for actinic keratosis (AK). This product theater is supported by Valeant. One of the biggest issues with AKs is that as soon as you see one, you often can’t go back, […]
June 29, 2013
-
LIVE BLOG: New Skies for Advanced Local Basal Cell Carcinoma [Product Theater: Genentech]
In this Live Blog from the SDPA Summer Conference, an MD representing Genentech presents on Erivedge as Novel Therapy for Appropriate Patients with Basal Cell Carcinoma. Erivedge is the 1st and only Hedgehog Pathway inhibitor approved by the FDA. Erivedge is for patients who aren’t candidates for surgery, or […]
June 29, 2013
Some of Our Sponsors
